Pharmaco-Imaging in Drug and Biologics Development

Imaging Platforms and Drug Development: An Introduction.- Imaging in Drug Development: Animal Models, Handling and Physiological Constraints.- Considerations for Pre-Clinical Laboratory Animal Imaging Center Design, Setup, and Management suitable for Biomedical Investigation for Drug Discovery.- Pharmaco-Imaging in Translational Science and Research.- The Role of Pharmacokinetics and Allometrics in Imaging: Practical Issues and Considerations.- Quantitative Imaging Using Autoradiographic Techniques.- Pre-Clinical Imaging in Oncology: Considerations and Recommendations for the Imaging Scientist.- Use of Radiolabelled Leukocytes for Drug Evaluation in Man.- Application of Bioluminescence Imaging (BLI) to the Study of the Animal Models of Human Infectious Diseases.- Pre-Clinical Imaging in BSL-3 and BSL-4 Environments: Imaging Pathophysiology of Highly Pathogenic Infectious Diseases.- Magnetic Resonance as a Tool for Pharmaco-Imaging.- Technologies and Principles of Mass Spectral Imaging.- Regulatory Considerations Involved In Imaging.

Mr. Brian R. Moyer is Owner/President of BRMoyer & Associates, LLC, Bedford, NH, consulting in medical imaging, radiation/chemical injury, and PK/TK services. He is under contract as a Sr. Science Advisor for HHS/BARDA, Washington, D.C., for Radiation-Chem countermeasure development. Mr. Moyer earned an M.S. in Pharmacology (Univ. of California, San Francisco), an M.S. in Toxicology (Univ. of San Francisco), and is board-certified in Nuclear Medicine Technology (CNMT). He has over 40 years in the imaging field with over 80 publications and has contributed toward six drug approvals. Dr. Narayan Cheruvu is Sr. Principal Clinical Pharmacologist at Covidien, St.Louis, MO. He earned a B.S. in Pharmacy (Andhra Univ.), an M.S. in Pharmacy (Institute of Technology-Banaras Hindu Univ., India) and a Ph.D. in Pharmaceutical Science (Nebraska Medical Center, Omaha, NE). Dr Cheruvu has more than 9 years in preclinical/clinical pharmacology, more than 20 publications and has contributed toward three drug approvals. Dr. Tom C.-C. Hu is a Project Officer at HHS/BARDA, Washington D.C., overseeing contracts for Radiation-Chem countermeasure development and rapid radiation biodosimetry. He is an Asst. Professor of Radiology (Medical College of Georgia) and served as Principal Scientist at GlaxoSmithKline PLC. Dr. Hu earned a B.S. in Chemistry (Univ. Pittsburgh), an M.S. and Ph.D. in Chemistry (Carnegie Mellon Univ), and an M.B.A (Villanova Univ).